RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Boston Scientific continues M&A run with Cortex buy

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Boston Scientific continued its active

November 4, 2024

How Institutions Can Support Ob/Gyns in Abortion-Restricted States

To better understand the ramifications of the Dobbs decision on clinical practice and on ob-gyns more personally, Kavita S. Arora, MD, MBE, an ob/gyn at

June 25, 2024

Cutting-edge ‘precision medicine’ shows great potential to improve diabetes care

Cutting-edge “precision medicine” has great potential to advance the diagnosis, treatment and ultimate prevention of different forms of diabetes, an international coalition of scientists reports

November 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.